Skip to content
Disclosery

CAXTON CORP

Follow

13F filer, CIK 1388551, Princeton, NJ

CAXTON CORP reported $4,024,354 across 7 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000919574-26-003017

Changes against Q4 2025 are not shown: its report omitted holdings under a confidential treatment request (11 positions on file), so every position would read as new.

The filing omits holdings under a confidential treatment request (H8). A later amendment may add them.

Period
2026-03-31
Reported value
$4.02M
Holdings
7
Top 10 weight
100%
New
Sold out

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0000919574-26-003017, largest first. % of portfolio is the value over $4,024,354, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GLDSPDR GOLD TRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,169 shares; 2025Q1: 1,298 shares; 2025Q2: 4,952 shares; 2025Q3: 7,286 shares; 2025Q4: 6,964 shares; 2026Q1: 7,623 shares 7,623$3.28M81.5%The filing omitted confidential holdings, a later amendment may add them.Timeline
BRK-BBERKSHIRE HATHAWAY INC DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,151 shares; 2024Q4: 1,133 shares; 2025Q1: 467 shares; 2025Q2: 632 shares; 2025Q3: 651 shares; 2025Q4: 710 shares; 2026Q1: 727 shares 727$348K8.66%The filing omitted confidential holdings, a later amendment may add them.Timeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 22,981 shares; 2024Q4: 22,981 shares; 2025Q1: 22,981 shares; 2025Q2: 22,981 shares; 2025Q3: 22,981 shares; 2025Q4: 18,773 shares; 2026Q1: 18,773 shares 18,773$162K4.03%The filing omitted confidential holdings, a later amendment may add them.Timeline
LXEOLEXEO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 17,851 shares; 2024Q4: 17,851 shares; 2025Q1: 17,851 shares; 2025Q2: 17,332 shares; 2025Q3: 17,332 shares; 2025Q4: 13,943 shares; 2026Q1: 13,943 shares 13,943$80K1.99%The filing omitted confidential holdings, a later amendment may add them.Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 15,557 shares; 2026Q1: 15,557 shares 15,557$64.2K1.6%The filing omitted confidential holdings, a later amendment may add them.Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 16,393 shares; 2025Q1: 16,393 shares; 2025Q2: 16,393 shares; 2025Q3: 16,393 shares; 2025Q4: 28,453 shares; 2026Q1: 28,453 shares 28,453$47.8K1.19%The filing omitted confidential holdings, a later amendment may add them.Timeline
ALXOALX ONCOLOGY HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 20,946 shares 20,946$42K1.04%The filing omitted confidential holdings, a later amendment may add them.Timeline

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000919574-26-003017 base2026-05-14acceptance time not in the bulk data set